MYD88 and lymphoma: Interestingly, MYD88 mutations were significantly increased in patients with lymphoma invasion of the bones (25.8% or 23/89; P = .0073), kidney/adrenal glands (30.3% or 10/33; P = .0258), breasts (42.2% or 19/45; P < .0001), testes (43.8% or 7/16; P = .0065), skin (34.8% or 8/23; P = .0177), and uterus/ovaries (50.0% or 4/8; P = .0241) compared to those without invasion of the bones (14.1% or 82/581), kidney/adrenal glands (14.9% or 95/637), breasts (13.8% or 86/625), testes (15.0% or 98/654), skin (15.0% or 97/647), and uterus/ovaries (15.3% or 101/662).